This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
HRS-9813 capsule.
HRS-9813 tablet.
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Maximum observed concentration of HRS-9813 capsule (Cmax)
Time frame: Day 1-Day 23.
Maximum observed concentration of HRS-9813 tablet (Cmax)
Time frame: Day 1-Day 23.
Area under the concentration-time curve from time 0 to infinity of HRS-9813 tablet (AUC0-inf)
Time frame: Day 1-Day 23.
Area under the concentration-time curve from time 0 to infinity of HRS-9813 capsule (AUC0-inf)
Time frame: Day 1-Day 23.
Adverse events (AEs)
Time frame: Day 1-Day 23.
Time to Cmax of HRS-9813 capsule (Tmax).
Time frame: Day 1-Day 23.
Time to Cmax of HRS-9813 tablet (Tmax).
Time frame: Day 1-Day 23.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.